News

It’s an exciting time for healthcare technologies. Here are the ones you need to look out for in the next ten years.

Evidence-based decisions can help guide end-of-life care.

As the U.S. population ages into declining health, accompanied by mobility challenges in getting to healthcare providers, innovative solutions to care include bringing the health system and medical procedures to patients’ homes.

Implementing a value-based model requires much more than simply changing the payment methodology.

Louisiana’s subscription model aims to rein in the hepatitis C epidemic in the state.

Behavioral health services company Beacon Health Options brings outpatient mental health therapy to a Texas Walmart store. Here’s how experts say it will affect managed care.

CVS Health adds new migraine drugs to its list of covered drugs, but excludes one rival treatment.

The partial government shutdown is affecting the country in many ways-but how is it interfering with biosimilar development?

While the government shutdown doesn’t directly affect HHS, the shutdown is having profound and long-lasting effects on the U.S. healthcare system.

HHS releases voluntary Cybersecurity Practices guidance. Industry analysts drill down deeper.

A new report details the financial strain rising drug prices are having on patients and hospitals alike.

How Horizon BCBSNJ’s Episodes of Care program engages physicians in certain specialties in the value-based continuum.

To help ensure your healthcare organization doesn’t get left behind, we’ve assembled the top six challenges the industry will face in 2019.

FDA cleared the first generic tablet version of a top-selling epilepsy drug.

The Five-Star Quality Rating System isn’t just a mechanism to improve the patient experience; it has also changed the industry from an insurer’s perspective. Here are three ways to buy into the CMS rating system as a means to continuous improvement.

A new study has revealing findings about health literacy and care.

New legislation designed to curb drug costs comes on the heels of many pharma makers raising prices this year as well as payers saying they expect higher drug acquisition costs.

FDA approved a record number of novel treatments in 2018.

With a new ruling against the Affordable Care Act (ACA), many worry about the fate of the biosimilar market. But will it be as detrimental as feared?

As the industry continues to look for strength in scale and strategic push toward ever-increasing verticalization, large-scale industry mergers and acquisitions will continue to be the norm during 2019-this and other 2019 predictions based on the digitization of healthcare.

Good company culture doesn’t just happen, you have to take charge and plan for it.

Here’s what healthcare organizations will face in the year ahead, and expert advice on how to deal.

The biggest drug categories and medications set for approval this year.

Here are certain facts that every executive responsible for managing populations at risk for prescription drug misuse should know as they make policy decisions affecting patient care and financial management.

This massive partnership is breaking down barriers and improving patient care.

What experts say will be the year’s biggest problems, and what can be done about them.

Soon after FDA warned the manufacturer involved in a massive nationwide recall of valsartan- and losartan-containing drugs, the recall is expanding. Find out why.

Two new therapies approved by FDA signal significant advancement in treating rare blood diseases.

Managed Healthcare Executive asked key opinion leaders: “What is your favorite movie that you recommend to other healthcare executives?” Here’s what they said.

Moving up the corporate ladder can be frustrating-here’s are six tips from industry experts